ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)
Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

NY Times Examines 'Controversial Pricing System' for BiDil, First Racially Targeted Medication

NitroMed officials on Thursday announced that they have set the price for the heart failure medication BiDil at $1.80 per pill -- a higher price than analysts expected and almost twice the price of rival treatments -- and that the company will establish an "unusually generous" assistance program for the estimated 75,000 patients without prescription drug coverage who could benefit from the medication, the... New York Times reports (Saul, New York Times, 7/8). FDA in June approved BiDil for use in black patients based on the results of a study that found the medication reduced their risk for heart disease. BiDil marks the first medication approved by FDA for use in a specific racial group (Kaiser Daily Health Policy Report, 6/24). Based on the dosage, treatment with BiDil will cost between $5.40 and $10.80 daily. However, under the assistance program, NitroMed will offer BiDil at no cost to patients with annual incomes of less than 300% of the federal poverty level, according to B.J Jones, marketing director for the company. In addition, patients without prescription drug coverage can purchase BiDil for $25 monthly, regardless of annual income. The program will benefit those who "unfortunately, so often, fall through the cracks, the quote, unquote working poor, with enough to keep food on the table but not enough to get the appropriate insurance," Jones said. Reaction
Several analysts have revised their sales estimates because of the higher price set for BiDil, "with many forecasting higher revenues than before," the Times reports. Pacific Growth Equities, which has a financial relationship with NitroMed, increased annual sales estimates for BiDil from $300 million to between $450 million to $500 million, according to Liana Moussatos, an analyst with the company. NitroMed officials said that the company will provide additional explanation for the decision on the price of BiDil at a shareholder meeting next week. Concerns
Steven Nissen and Jonathan Sackner-Bernstein, cardiologists who served on the FDA advisory committee that recommended approval for BiDil, raised concerns that not all the eligible patients will participate in the assistance program. "I'm skeptical about these plans," Sackner-Bernstein said, adding, "Since they require doctors to send in forms, they don't work as well as they are supposed to." According to the Times, NitroMed "runs another risk by pricing the drug high" because some physicians might attempt to prescribe the generic ingredients of BiDil -- isosorbide dinitrate and hydralazine -- to patients who cannot afford the medication. The "generics are not available in the exact doses contained in the BiDil pill," but "some doctors are willing to experiment ... to achieve similar results," the Times reports. BiDil likely will reach the market by Monday (New York Times, 7/8).

NitroMed

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on BiDil.





NY Times analizeazã "Controversate sistem de stabilire" pentru BiDil, Prima rasial Targeted medicaþie - NY Times Examines 'Controversial Pricing System' for BiDil, First Racially Targeted Medication - articole medicale engleza - startsanatate